Background: The prognosis of advanced testicular cancer has improved considerably after the introduction of cisplatin-based combination chemotherapy. The improved prognosis of testicular cancer has brought the long-term toxicity of the treatment into focus.
Background
Testicular cancer is one of the most common cancer diseases among 15-35-year-olds [1] . Although some patients are cured after orchidectomy alone or after operation followed by retroperitonea! lymph node dissection, the majority of patients with non-seminomatous germ-cell cancer need systemic treatment (50%-70%) [2, 3] . The prognosis of advanced testicular cancer has improved considerably after the introduction of cisplatin-based combination chemotherapy (PVB: cisplatin, vinblastine, and bleomycin and later PEB: cisplatin, etoposide, and bleomycin) for the treatment of patients with this disease [3] . The improved prognosis of testicular cancer has brought the long-term toxicity of the treatment and quality of life after treatment into focus.
Several studies have evaluated the long-term toxicity of cisplatin-based chemotherapy for testicular germ-cell cancer [4, 5] . However, to our knowledge, no prospective studies of long-term toxicity have been carried out in such patients followed more than 10 years.
Acute nephrotoxicity, indicated by impaired glomerular filtration rate (GFR) is well described during cisplatin treatment [6] , and persistent impairment of GFR is seen in approximately 50% of the patients 42-97 months after treatment [7] .
Significant clinical pulmonary toxicity has been reported in up to 10% of bleomycin-treated patients [8] . Measurement of carbon monoxide diffusion capacity (TLco) combined with physical examination of the patients is still considered the most suitable method to determine pulmonary toxicity in these patients [9] . Pulmonary toxicity defined as more than 35% decrease in TLco was found in 15 of 18 patients during treatment [10] . At follow-up 42-97 months after PVB treatment, a median decrease in TLco to 72% of the expected value was seen in smokers, while TLco in non-smokers was insignificantly lower than expected [11] .
Raynaud's phenomenon, probably caused by hyperreactivity of the sympatic nervous system, is observed in 40%-45% of the PVB-treated patients [12] [13] [14] . Vinblastine and cisplatin are neurotoxic agents, which have been shown to cause autonomic neuropathy and paresthesia in approximately 1/3 of the patients investigated 49-106 months after PVB treatment [15, 16] . However, impaired peripheral nerve function have been measured in 3/4 of the patients.
It is well documented that cisplatin-based chemotherapy may have a harmful effect on spermatogenesis and Leydig cell function [17] [18] [19] [20] [21] [22] . Nearly all patients become azoospermic during cisplatin-based treatment but at least some degree of recovery is seen in the majority chromium edetate ( 5l Cr-EDTA) with an activity of 100 uCi/ml. A blood sample was drawn 240 minutes after injection and clearance was determined from standard curves [23] Only differences exceeding 8 ml/min/1.73 m 2 were considered significant [24] , One patient was excluded from evaluation of renal function because of pre-treatment obstruction of the ureteres.
Blood pressure was measured according to recommendations from the World Health Organization (WHO) [25] .
Pulmonary function
The lung function was tested by measurements of total lung capacity (TLC), vital capacity (VC), forced expiratory volume in one second (FEV1), and diffusion capacity for carbon monoxide (TLco). The diffusion capacity for carbon monoxide was assessed by the singlebreath technique as described by Ogilvie et al. [26, 27] . corrected for abnormal values of serum haemoglobin as described by Dinakara et al. [28] . The pulmonary function was compared with the laboratory normal values based on a population sample of 125 non-smokers [29] . The values are given as absolute values or as a percentage of the values expected from the reference group, corrected for age. sex. weight, and height of the patients during the first two years after treatment, while no further recovery is expected later [17, 18, 22] .
The aim of this study was to evaluate the long-term toxicity 10-15 years after treatment in a group of patients treated with PVB for testicular cancer. We have focused on nephro-, neuro-, pulmonary-, and gonadal toxicity.
Patients and methods
Between March 1979 and December 1983 patients referred to The Finsen Institute with metastatic, non-seminomatous, germ-cell cancer were treated with cisplatin, vinblastine, and bleomycin The chemotherapy consisted of 6 courses of cisplatin 20 mg/m 2 I.V , days 1-5, and vinblasline 6 mg/m 2 i.v.. days 1 and 2 every 3 weeks. Bleomycin was given i.m. in a dose of 15 mg/m 2 weekly for 10 weeks and then as 5 mg/m 2 weekly for 8 weeks. Cisplatin was administered with hydration and mannitol-forced diuresis.
Renal and pulmonary function were evaluated before initiation and regularly after treatment. Neuro-and gonadal toxicity were evaluated after a median follow-up time of 76 (43-98) months after PVB treatment (called follow-up 1). These examinations were done on 26 patients. Of these patients, 22 participated in a re-evaluation after a median follow-up period of 159 (135-186) months after treatment (called follow-up 2). Two patients had died between the two follow-up investigations, one of relapse and one of myocardial infarction. Two patients, who were healthy, did not want to participate in the reevaluation One patient had undergone thoracotomia because of mature teratoma, developed since the previous follow-up. Orchidectomy was done before chemotherapy if the patients had a testicular tumor or carcinoma in situ. However, in one patient orchidectomy was not done because he only had extra-gonadal disease. Retroperitoneal lymph node dissection was not done routinely but a laparothomy or thoracothomy was done after chemotherapy in case of residual tumor. Three patients were treated with abdominal radiotherapy 2 Gy x 20. Patient characteristics are given in Table 1 .
Renal function
Glomerular filtration rate (GFR) was determined by calculation of chromium edetate clearance after intravenous injection of 1 ml 51
Neuro-toxicity
Sensorv nerve function was assessed by measurement of the vibratory perception threshold (VPT) by a biolhesiometer (Ohio, Mass.) according to the method described by Nielsen [30] . The results were compared with a reference group of healthy age-matched controls.
Parasympathetic nerve function: 1) Heart rate response to Valsalva's manoeuvre: the patient was asked to blow into a mouth piece keep a pressure of 40 mmHg for 15 seconds. The pressure was measured by an aneroid manometer, connected to the mouth piece. The test was performed three times at one minutes intervals. An electrocardiogram was continuously recorded. The Valsalva ration was calculated as the ratio between the longest R-R interval after the manoeuvre and the shortest R -R interval during the manoeuvre. The mean value of the 3 tests was used [31] . 2) Heart rate variation during deep breathing-the patient sat quietly and breathed deeply (six breath a minute) An electrocardiogram was recorded continuously during the test. The maximum and minimum R-R intervals during each breathing cycle were converted to beats/minute. The results were expressed as the mean of the differences between maximum and minimum heart rates for the six measured cycles [32] , Sympathetic nerve function was evaluated by measuring the postural changes in blood pressure [33] Data on autonomic nerve function were analysed using reference values as recommended by Ewing and Clarke [33] ,
Testicular function

Semen analyses
All semen analyses were performed in the same laboratory, in accordance with the guidelines of the World Health Organization [34. 35] , The specimens were delivered within two hours of ejaculation. The following parameters were analysed: volume, total sperm count, sperm concentration, morphology, motility and vitality. Mean values were used for calculations in patients, who delivered more than one ejaculate.
Hormone analyses
Serum values of follicle stimulating hormone (FSH). luteinizing hormone (LH) and testosterone were analysed by radioimmuno-assay. The WHO Standard second IRP 78/549 for FSH and the WHO standard first IRP 68/40 for LH were used. LH and FSH levels were expressed in international units per litre and the reference intervals were 1.5-10.5 IU'1 and 1.1-7.9 IUM. respectively. Testosterone values were expressed in nmol'l and the reference interval was 1.10-34 nmol I. 
Statistics
Paired two-tailed Mest was used for comparison of the data at the first follow-up with the data obtained at the second follow-up. Wilcoxon's signed rank test for paired data was used if the tested difference was not normally distributed. Shapiro-Wilk W-test was used to test for normality. Correlations between the cumulated dose of cisplatin and GFR and between cumulated bleomycin dose and TLco were analysed by calculation of Spearman's correlation coefficient.
Results
All 22 men reported physical and social well-being. One man was unemployed and one was on disablement pension which already before chemotherapy had been granted because of mental disorder. The remaining 20 men were employed in a wide range of different jobs and all men denied any limitations in their social or working life related to the previous cancer disease or its treatment. No patients reported present or previous diseases, which could negatively effect the examined parameters.
Renal function
The results of the evaluation of renal function are shown in Figure 1 . GFR decreased in 80% of the patients during treatment. A progressive decrease in GFR after treatment was observed in 2 of 21 patients at follow-up examination after 76 (43-98) months (follow-up 1), while 10 patients had an improvement in GFR from the post-treatment period until follow-up 1. A further increase in GFR was seen in four patients at re-evaluation after a median of 159 (135-186) months (follow-up 2), while no patient had a decrease of GFR during this period. At follow-up 2, nine patients had lower GFR than the pre-treatment level and three patients higher values. Even though the level of GFR was still significantly lower at last examination all the patients had GFR within the reference interval for healthy men at that moment. We could not see any correlation between cumulated cisplatin dose and GFR (P = 0.19). No trends were seen in the development of systolic or diastolic blood pressure and, in spite of the ageing of the patients, no statistically significant differences were seen between blood pressure measured at follow-up 1 and follow-up 2.
Pulmonary function
The data from the pulmonary evaluation are shown in Table 2 and Figure 3 . The present study showed that TLco decreased to a median of 86% of expected value (range 56%-133%) already before chemotherapy, and an insignificant increase was seen after the first course of chemotherapy and a decrease was seen again after the six courses of chemotherapy (P -0.06). No significant change in the values given as percentage of expected value or the absolute values of TLco was seen in the post-treatment period until follow-up 1. A large and statistically significant increase of TLco levels given as percentage of expected values for age, weight and height was observed between follow-up 1 and follow-up 2.
Moreover the absolute values seemed to increase during this period, even though this increase did not reach the 95% significance level (P -0.10).
The following lung function tests wer normal at follow-up as compared to reference levels: TLC, VC, and FEV1. The decrease in forced expiratory volume in 1 sec (FEV1) was biologically insignificant and no difference was seen between the values of at follow-up 1 and follow-up 2, when the values were expressed in percent of expected values (P = 0.41). We could not detect any correlation between the cumulated bleomycin dose and pulmonary function (P = 0.61).
There were no deaths due to lung fibrosis during the follow-up period and none of the patients reported symptoms of respiratory dysfunction.
Neurotoxicity
Sensory nerve function: 11 of 22 patients reported symptoms of paresthesia at follow-up 1, while only 3 patients reported this symptom at follow-up 2. Vibration perception threshold: The results of vibration perception threshold are shown in Figure 3 . In 10 patients, the values were within normal range both at first and second follow-up examination. The threshold normalised in 7 of 11 men with previously increased levels.
Parasympathetic nerve function: We did not see statistically significant differences between the results of deep breathing test or response to Valsalva's manoeuvre at follow-up 1 and follow-up 2. The vasalva-test was below reference value in 3 of 22 patients at follow-up 1 and in 5 of 22 patients at follow-up 2.
Sympathetic nerve function: We observed a larger and statistically significant increased response in bloodpressure to standing (P = 0.001) at follow-up 1 after treatment than at follow-up 2 (Table 3) . Postural hypotension was more marked in 17 patients, unchanged in 4, and improved in 1 patient at the later examination as compared with the first examination. No patients reported symptoms of postural hypotension. Raynaud's phenomenon was reported by 10 at follow-up 1 and 8 patients at follow-up 2. The phenomenon disappeared in six patients and arose in four patients between the two examinations. Two of the latter four patients had measurable signs of impaired sympathetic nerve function already at first follow-up examination.
Testicular function
Semen analysis: No differences were detected in median total sperm count (1. (Figure 4 ), or % motile sperms (P = 0.75) between the two follow-up examinations. The proportion of sperm with normal morphology was lower (median 31% (17%-50%) versus 37% (26%-53%)) (P = 0.02) at first follow-up than at second follow-up. Although no statistically significant improvement of sperm counts was seen, one patient, who had azoospermia at first follow-up, achieved motile sperms in the semen at second follow-up examination (0.0 to 1.0 x 10 6 ) and a remakable increase was seen in two patients who had severe oligozoospermia (0.13 to 50 x 10 6 and 0.30 to 4.1 x 10 6 ). One of these patients had a history of infertility after treatment and his wife was inseminated with donor semen in 1988. However, the couple achieved spontaneous pregnancy in 1992. One patient with sperm concentration 16 x 10 6 /ml in 1988 had azoospermia in 1995.
Before treatment, 3 of the 10 patients who wanted pregnancy reported a history of infertility, defined as more than two years' attempt by the couple to achieve pregnancy without success. After treatment, 9 of 16 for whom his topic was relevant had a history of infertility. Six men had fathered children before, and nine after PVB treatment. One of these children was born after assisted fertilisation. One man had fathered a Child both before and after treatment with PVB.
Hormone analyses: Impairment of spermatogenesis was confirmed by increased levels of FSH at both first (median 19 IU/1 (4.1-67 IU/1)) and second follow-up (median 21 IU/1 (7.7-56 IU/1)) ( Figure 5 ). No significant change (P= 0.18) was observed from first evaluation 3-7 years after treatment to second follow-up more than 10 years after PVB treatment.
Leydig cell function was evaluated by measurement of LH and testosterone. The values of LH were significantly higher (P< 0.001) at first follow-up (median 21 IU/1 (7.7-56 IU/1)) than at second follow-up (median 13 IU/1 (3.8-43 IU/1). Testosterone levels too were significantly higher (P -0.003) at first follow-up (median 19 nmol/1 (4.0-31 nmol/1) than at second follow-up (median 16 (5.5-21 nmol/1)). Impaired libido compared to pre-treatment level and erectile or ejaculatory dysfunction were reported by 3 men. The values of serum testosterone were low in all these three men (6.9, 11.2, 5.5, respectively). One patient reported impaired libido during the first year but normalisation afterwards.
Discussion
A general concern in patients treated with cisplatin-based chemotherapy for testicular germ-cell cancer has been that chemotherapy-induced side-effects could increase the age-related impairment of renal function, lung function, testicular function, and age-related risk of neuropathy. This study demonstrates clearly that patients who had been treated with six cycles of PVB for disseminated testicular germ-cell cancer have a social life without feeling limitations due to the treatment or the disease more than 11 years after treatment. Generally the therapyinduced dysfunctions improved after the end of treatment and some of the side-effects may even disappear many years after teratment in spite of increasing age. The only spontaneously reported symptoms that could be related to the cancer treatment were infertility, sexual dysfunction in few patients, mild paresthesia, and Raynaud's phenomenon. 
Renal toxicity
In the present study, GFR decreased in 80% of the patients during treatment. Hydration and mannitolforced diuresis during treatment have reduced the degree of cisplatin-induced nephrotoxicity, and we have previously observed an 18% decrease of GFR during PVB treatment in these patients [33] . This is in accordance with other studies, which have shown a reduction in FGR of 12%-39% 1-2 years after 4-6 cycles of cisplatinbased chemotherapy [7, 15, [36] [37] [38] [39] .
Overall GFR decreased significantly during treatment but a statistically significant increase was seen after treatment. None of the patients experienced a further decrease of GFR during follow-up more than 43 months after chemotherapy. Even though the level of GFR was still significantly lower at last follow-up examination than pre-chemotherapy levels, all the patients have now GFR values withint the reference interval for healthy men.
No trends were seen in the systolic or diastolic blood pressure and, in spite of ageing, no statistically significant differences were ween between blood pressure measured at follow-up 43-98 months and 135-186 months after treatment. We did not see any correlation between cisplatin dose and the levels of blood pressure and EDTA clearance or changes in these values. However, the lack of correlation in the present study does not mean that a correlation between these factors does not exist, but the lack could be due to relatively uniform cisplatin dose levels in these patients and the relative small number of patients.
Pulmonary toxicity
Bleomycin-induced pulmonary damage caused several deaths before the introduction of monitoring of lung diffusion capacity. Measurement of TLco together with physical examination of the patients is still considered the most suitable method to determine pulmonary toxicity in these patients [9, 40] . We found that TLco was significantly reduced even before treatment. This is thought to be associated with oedema of the alveolar membrane caused by tumour products [41] . This might explain the increase in TLco observed during the first course of treatment when tumour regression was induced and before sufficient amounts of bleomycin had been accumulated to cause a measurable decrease in TLco. The decrease in Tlco during further treatment was significant in smokers but insignificant changes were seen in non-smokers.
In the present long-term follow-up, the decrease in TLco immediately after therapy remained unchanged during the first observation period, but surprisingly a rise in TLco was seen in the second period of observation more than 43 months after PVB treatment. This observation means that the bleomycin-induced changes are reversible more than 43 months after treatment in some patients. The discrepancy between the present study and previous studies which have shown reversibility of TLco during the firest 1-2 years after treatment [3, 42] may be due to differences in cumulated doses and /or differences in schedules of bleomycin administration. This observation could indicate that the time to recovery is correlated to cumulated dose and duration of exposure.
Enhanced toxicity has been reported in bleomycintreated patients who have been ventilated with high exogen concentrations during anaesthesia [43] . These observations have resulted in concerns about the use of high oxygen pressure during anaesthesia for patients previously treated with bleomycin. Moreover two case reports have reported fatal lung insufficiency in divers previously treated with bleomycin [44, 45] . This has led to restrictions in the right to obtain diving certificate in many countries. These restrictions should be reconsidered after the present observation, of normalisation of TLco in these patients. However, further clarification requires more long-term clinical observations and reports on patients who have been diving despite previous bleomycin treatment would be very valuable.
Neurotoxicity
It has previously been shown that cisplatin and vinblastine treatment cause a dose dependent sensory type of peripheral neuropathy in the majority of patients [46] [47] [48] [49] [50] [51] . In accordance with these observations, 83% of the patients complained of paresthesia immediately after treatment [15] . However, this side effect seemed to decline continuously after treatment to 50% prevalence at follow-up 4-9 years after chemotherapy and to 14% prevalence at second follow-up 11-15 years after treatment. The reported decline in neurotoxicity was verified by normalisation of vibration perception threshold at the latest follow-up in 7 of 11 patients who had increased threshold at follow-up 4-9 years after chemotherapy. These findings are stressed by the previous observation of close correlation between vibration perception threshold and measurements of peripheral nerve function [15] . We did not perform measurement of Raynaud phenomenon at last follow-up examination. However clinical Raynaud phenomenon, which is supposed to be a combination of a vasospastic phenomenon and a direct effect on small arteries [13] , disappeared in six patients arose in four patients. Of these patients two had subclinical Raynaud phenomenon at previous follow-up examination.
Gonadal toxicity
The patients in the present study were all (except one) orchidectomised prior chemotherapy, some had postchemotherapy resection of residual tumor and three had abdominal radiotherapy prior to chemotherapy. All these treatment modalities may contribute to the effect on semen quality in these heavily treated patients. Furthermore the disease itself seems to be related to poor semen quality [52] . In the present study we did not have the possibility to distinquish between the effects of the different treatment modalities. However the scope of this work was to clarify the course of the long-term toxicity.
The effects of chemotherapy regimens including cisplatin on testicular function have been shown to be dosedependent [20, 53] . Thus the very poor semen quality with very low sperm concentrations and total sperm counts found in the present study compared to other studies 17, 20, 53. 54] might be due to the relatively high cumulated doses of cisplatin given to these patients (median 583 mg/m 2 ). Spermatogenesis is thought to recover during the first two years after treatment but we saw improvement of spermatogenesis more than four years after treatment in some patients and even recovery from azoospermia in one patient. The relationship between semen quality and fertility is still fairly obscure but in this study the very poor semen quality was accompanied by a high number of patients who reported a history of infertility. The fertility aspects are particularly relevant in these patients because they are excluded from the possibility of adoption of children in many countries because of the previous cancer disease. In the light of their social and physical well-being more than 11 years after treatment, we think that it should be discussed whether these patients should have access to adoption some years after end of treatment.
Impairment of spermatogenesis was confirmed by increased levels of FSH at both first and second follow-up.
The values of LH and testosterone were significantly higher at first follow-up than at second follow-up. This difference cannot be explained by normal ageing, because LH does not decrease with increasing age in healthy men and testosterone should be stable during the study period in this age-group in accordance with our reference group of 193 healthy men. Thus the observation of decreasing LH level in nearly all patients resulting in decreased testosterone values more than five years after PVB treatment could be explained by alterations in pituitary or hypothalamic function or a decreased level of protein-binding of testosterone. However this observation remains to be confirmed in more patients. It was remarkable that all three men who reported impaired libido compared to pre-treatment level had low values of serum testosterone.
Conclusion
The present study demonstrates clearly that patients treated with cisplatin-based chemotherapy are physically and socially well. Increasing incidence of pulmonary-, neuro-, and renal dysfunction could be expected with ageing in these patients due to imparied capacity of the organs after treatment. In contrast to this anticipation, we observed remarkable improvements in pumonaryand renal function, and recovery from neurotoxicity during the long-term follow-up. Only gonadal toxicity seems to be persistent although improvement was seen in a few patients even many years after treatment. A history of infertility due to the disease itself and/or the chemotherapy is frequent in these patients.
